Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PUNCH CD Open-Label: RBX2660 for Recurrent CDI
NCT02589847Phase 2Completed
- Sponsor
- Rebiotix Inc.
- Start
- Oct 2015
- Primary completion
- Jun 2017
- Modality
- Live Biotherapeutic Products
- Countries
- 2
01
Overview
A Phase 2 trial of RBX2660 in recurrent Clostridioides difficile infection (rCDI), sponsored by Rebiotix Inc.. Started Oct 2015; status: completed.
02
Drugs
RBX2660
03
Conditions
recurrent Clostridioides difficile infection (rCDI)
Beyond the preview
Go deeper on NCT02589847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02589847.